Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for ATS and Opioid Dependence in Malaysia
NCT01863251Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine in stimulant use disorder (SUD), sponsored by Yale University. Primary endpoint: Amphetamine-type stimulant Use at 4 months. Started May 2013; status: completed.
02
Drugs
atomoxetine
03
Conditions
stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT01863251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863251.